Collegium Pharmaceutical (COLL) AI Stock Analysis

• Market Cap: $1.13B
• Dividend Yield: N/A
• Average Volume (3M): 373.09K
• Price to Earnings (P/E): 39.3
• Beta (1Y): 0.43
• Revenue Growth: 26.34%
• EPS Growth: -32.79%
• Country: US
• Employees: 357
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.25
• Shares Outstanding: 31,502,127
• 10 Day Avg. Volume: 458,928
• 30 Day Avg. Volume: 373,091
• PEG Ratio: 0.40
• Price to Book (P/B): 4.04
• Price to Sales (P/S): 1.46
• P/FCF Ratio: 4.55
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $45.50
• Price Target Upside: 7.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: $45.00 ▲(6.38% Upside)

Collegium Pharmaceutical's strong financial growth and positive earnings call sentiment are key strengths, driving the overall score. However, high leverage, overvaluation concerns, and technical indicators suggesting an overbought condition are notable risks that temper the score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong demand for Collegium's products, particularly in the pain management sector, which is likely to sustain the company's market position and drive future earnings.

Cash Flow Generation

Strong cash flow generation enhances Collegium's financial flexibility, allowing for strategic investments, debt reduction, and shareholder returns, supporting long-term financial health.

Product Portfolio Strength

The growth in Jornay PM underscores the strength of Collegium's product portfolio, enhancing its competitive advantage and market share in the pharmaceutical industry.

Negative Factors

High Leverage

High leverage can pose financial risks by increasing interest obligations and limiting the company's ability to invest in growth opportunities, potentially affecting long-term stability.

Declining Net Profit Margins

The decline in net profit margins suggests rising costs or pricing pressures, which could impact Collegium's profitability and ability to reinvest in its business over the long term.

Increased Operating Expenses

Rising operating expenses may strain Collegium's profitability and cash flow, potentially limiting its ability to fund growth initiatives and maintain competitive pricing.

Collegium Pharmaceutical Business Overview & Revenue Model

Company Description

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products for the treatment of pain and other central nervous system conditions. The company primarily operates in the pharmaceutical sector, with a core focus on abuse-deterrent formulations of medications to address the opioid crisis and improve patient safety. Collegium's flagship product is Xtampza ER, an extended-release oxycodone formulation designed to provide effective pain management while minimizing the potential for misuse.

How the Company Makes Money

Collegium Pharmaceutical generates revenue primarily through the sale of its prescription drugs, particularly Xtampza ER. The company employs a revenue model based on direct sales to healthcare providers and pharmacies, as well as through partnerships with other pharmaceutical companies for the distribution of its products. Additionally, Collegium may receive royalty payments from licensing agreements or collaborations, enhancing its revenue streams. The ongoing demand for pain management solutions, particularly those that are abuse-deterrent, positions the company to capitalize on market needs, thereby contributing to its overall earnings.

Collegium Pharmaceutical Financial Statement Overview

Summary

Collegium Pharmaceutical shows strong revenue growth and operational efficiency, with healthy margins and cash flow metrics. However, high debt levels and a declining net profit margin present potential risks. The company should focus on managing its leverage and improving profitability to enhance financial stability.

Income Statement

Collegium Pharmaceutical has shown a consistent revenue growth trend, with a TTM revenue growth rate of 7.08%. The gross profit margin is strong at 56.69%, indicating efficient cost management. However, the net profit margin has decreased to 5.13% from 10.96% in the previous year, suggesting increased expenses or other financial pressures. The EBIT and EBITDA margins are healthy, reflecting good operational efficiency.

Balance Sheet

The company has a high debt-to-equity ratio of 3.57, indicating significant leverage, which could pose financial risks. The return on equity has decreased to 15.60% from 30.23% in the previous year, suggesting reduced profitability for shareholders. The equity ratio is not explicitly provided, but the high leverage suggests a lower proportion of equity in the capital structure.

Cash Flow

Collegium Pharmaceutical has demonstrated strong cash flow performance with a 43.36% growth in free cash flow. The operating cash flow to net income ratio is 0.44, indicating a solid conversion of income to cash. The free cash flow to net income ratio is nearly 1, showing efficient cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	757.07M	631.45M	566.77M	463.93M	276.87M	310.02M
Gross Profit	433.17M	377.34M	326.17M	209.49M	150.62M	179.84M
EBITDA	333.09M	341.70M	308.33M	168.76M	86.58M	118.07M
Net Income	58.44M	69.19M	48.16M	-25.00M	71.52M	26.75M
Balance Sheet
Total Assets	1.61B	1.66B	1.14B	1.17B	692.08M	643.84M
Cash, Cash Equivalents and Short-Term Investments	285.86M	162.76M	310.55M	173.69M	186.43M	174.12M
Total Debt	813.99M	979.91M	674.28M	872.79M	258.75M	266.58M
Total Liabilities	1.33B	1.43B	947.88M	979.29M	489.15M	457.81M
Stockholders Equity	274.81M	228.84M	195.43M	194.84M	202.93M	186.03M
Cash Flow
Free Cash Flow	289.30M	203.33M	274.29M	122.61M	101.61M	-279.83M
Operating Cash Flow	290.92M	204.98M	274.75M	124.23M	103.56M	93.94M
Investing Cash Flow	-55.23M	-287.76M	-70.81M	-573.69M	-1.94M	-373.77M
Financing Cash Flow	-129.70M	-60.60M	-140.18M	436.72M	-89.30M	286.47M

Collegium Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 42.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COLL, the sentiment is Positive. The current price of 42.3 is above the 20-day moving average (MA) of 35.42, above the 50-day MA of 35.70, and above the 200-day MA of 31.79, indicating a bullish trend. The MACD of 1.14 indicates Negative momentum. The RSI at 79.96 is Negative, neither overbought nor oversold. The STOCH value of 83.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COLL.

Collegium Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	74 Outperform	$1.13B	9.00	18.32%	―	1.37%	-18.10%
COLL	70 Outperform	$1.13B	39.25	22.96%	―	26.34%	-32.79%
ANIP	62 Neutral	$1.96B	―	-2.82%	―	38.68%	-160.14%
AVDL	61 Neutral	$1.85B	―	-0.32%	―	79.88%	99.60%
SUPN	55 Neutral	$2.64B	―	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCRX	46 Neutral	$981.78M	―	-15.57%	―	2.25%	-301.59%

Collegium Pharmaceutical Corporate Events

Collegium Pharmaceutical Reports Record Q3 2025 Results

Collegium Pharmaceutical Inc., a biopharmaceutical company, focuses on developing and commercializing innovative medications for pain management and neuropsychiatry, with a notable product, Jornay PM, for ADHD treatment.

Collegium Pharmaceutical Reports Strong Q3 2025 Financial Results

Collegium Pharmaceutical reported strong financial results for the third quarter of 2025, with record net revenue of $209.4 million, a 31% increase year-over-year. The company raised its full-year 2025 guidance, expecting net revenue between $775 to $785 million and adjusted EBITDA between $460 to $470 million. The growth was driven by a 20% increase in Jornay PM prescriptions and a robust performance in its pain portfolio. The company continues to focus on strategic business development and disciplined capital deployment to support patient care and drive shareholder value.

The most recent analyst rating on (COLL) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.

Collegium Pharmaceutical Reports Strong Q2 2025 Results

Collegium Pharmaceutical Inc., a biopharmaceutical company based in Stoughton, Massachusetts, specializes in pain management medications and neuropsychiatry treatments, notably Jornay PM for ADHD. In its latest earnings report, Collegium announced record quarterly net revenue of $188 million, marking a 29% increase year-over-year. The company also reported significant growth in its ADHD medication, Jornay PM, with net revenue reaching $32.6 million, a 23% increase in prescriptions year-over-year. Additionally, the pain portfolio generated $155.4 million in net revenue, a 7% increase from the previous year.

Collegium Pharmaceuticals Reports Strong Earnings and Growth

Collegium Pharmaceuticals’ recent earnings call highlighted a robust financial performance, marked by significant revenue growth and successful execution of strategic priorities. Despite increased operating expenses and a decline in GAAP net income, the overall business outlook remains optimistic with raised financial guidance and a strong commitment to shareholder value.

Collegium Pharmaceutical Reports Record Q2 2025 Revenue

On August 7, 2025, Collegium Pharmaceutical reported its financial results for the second quarter of 2025, showcasing a record quarterly net revenue of $188.0 million, a 29% increase year-over-year. The company raised its full-year 2025 revenue guidance to $745-$760 million and adjusted EBITDA guidance to $440-$455 million. Notably, Jornay PM net revenue reached $32.6 million, with prescriptions growing by 23% year-over-year. The pain portfolio also saw a 7% revenue increase. Collegium announced a $150 million share repurchase program and completed a $25 million accelerated share repurchase, emphasizing its focus on enhancing shareholder value.

The most recent analyst rating on (COLL) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.